NCT00074646View on ClinicalTrials.gov

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

June 30, 2005

Conditions
GlioblastomaMalignant Gliomas
Interventions
DRUG

CC-8490

Trial Locations (1)

20892-8200

Neuro Oncology BranchNational Cancer Institute, Bethesda

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY

NCT00074646 - Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas | Biotech Hunter | Biotech Hunter